Traditional Chinese medicine composition for invigorating spleen, tonifying kidney, securing essence and dispersing blood stasis as well as preparation method and application of traditional Chinese medicine composition

Through the ratio of traditional Chinese medicine compositions such as ginseng, Rehmannia, Poria, Schisandra chinensis, Chuanxiong and other Chinese medicine compositions, Chinese medicine compositions that strengthen the spleen and kidneys, consolidate essence and remove blood stasis were prepared, which solved the problem of component quality control and the insufficient efficacy of Western medicine treatment, and achieved the goal of achieving the Significant clinical efficacy and safety.

CN118903291APending Publication Date: 2024-11-08ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202310508293.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The component quality standards of existing Chinese patent medicines for the treatment of chronic glomerulonephritis are difficult to control, and some patients are not satisfied with the efficacy of Western medicine treatment, and there are adverse drug reactions and high cost restrictions.

Method used

The traditional Chinese medicine compositions that strengthen the spleen and kidney, consolidate essence and remove blood stasis are prepared by using the combination of ginseng, Rehmannia, Poria, Schisandra chinensis and other Chinese medicines, and the traditional Chinese medicine compositions that strengthen the spleen and kidneys, consolidate essence and remove blood stasis are prepared by decoction and extraction and concentration process, and granules are made for treatment. Chronic glomerulonephritis, simplified formula composition and easy quality control.

Benefits of technology

It significantly reduces the symptoms of spleen and kidney deficiency syndrome in patients, reduces urine protein, improves immune function, and reduces renal inflammatory response. It has safety and significant clinical efficacy, and is better than basic Western medicine treatment alone.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903291A_ABST
    Figure CN118903291A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for invigorating spleen, tonifying kidney, securing essence and dispersing blood stasis as well as a preparation method and application thereof. The traditional Chinese medicine composition for invigorating spleen, tonifying kidney, securing essence and dispersing blood stasis comprises the following raw material components in parts by weight: 5-6 parts of ginseng, 8-10 parts of prepared rehmannia root, 8-10 parts of poria cocos, 3-4 parts of schisandra chinensis and 5-6 parts of ligusticum wallichii. The composition disclosed by the invention can effectively cope with the basic pathogenesis of CGN spleen and kidney deficiency, subtle downward flow and blood stasis retention, and is beneficial to homogenized treatment of the disease. The traditional Chinese medicine composition is simple in raw material composition, easy in quality control and high in effective rate when being used for treating the CGN spleen and kidney deficiency syndrome, clinical symptoms of the spleen and kidney deficiency syndrome of a patient can be remarkably relieved, urine protein is reduced, the immune function is improved, kidney inflammatory response is relieved, the kidney protection effect is achieved, and the clinical curative effect of the traditional Chinese medicine composition combined with western medicine basic treatment is remarkably superior to that of pure western medicine basic treatment. And no obvious adverse reaction occurs in the medication process, and the application is safe.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for strengthening the spleen and kidney, consolidating essence and removing blood stasis, and a preparation method and application thereof. Background Art

[0002] Chronic glomerulonephritis (CGN) is the leading cause of chronic kidney disease (CKD) progressing to end-stage renal disease (ESRD) in my country. Its course is progressive, seriously affecting the quality of life of patients, consuming a large amount of medical resources, and bringing a heavy burden to patients and society. Its pathogenesis includes immune disorders, inflammatory response, oxidative stress, lipid abnormalities, etc. At present, the treatment of CGN in Western medicine mainly adopts optimized supportive treatment (including dietary management, ACEI / ARB, SGLT2 inhibitors, etc.), and glucocorticoids and immunosuppressants are used for patients with medium and high risks of progression to ESRD. However, the clinical efficacy of some patients is still unsatisfactory. At the same time, drug-related adverse reactions and the high cost of some drugs limit the use of some people.

[0003] Proteinuria is an independent risk factor for the progression of CGN. Reducing urine protein is of great significance for preventing or delaying the progression of CGN. Therefore, the treatment of CGN proteinuria is particularly important. TCM syndrome differentiation and treatment of CGN has the advantages of reducing urine protein, improving clinical symptoms and individualized treatment characteristics. The Chinese patent medicines currently used in China for the treatment of CGN mainly include: Jinshuibao Capsules, Bailing Capsules, Shenyan Kangfu Tablets, Shenyan Shu Tablets, Huangkui Capsules, etc. Among them, Jinshuibao Capsules and Bailing Capsules are mainly used to nourish the lungs and kidneys. Shenyan Kangfu Tablets are mainly used to treat qi and yin deficiency and toxic heat. Shenyan Shu Tablets are mainly used to treat spleen and kidney yang deficiency, and their effects are to nourish the kidneys and strengthen the spleen, promote diuresis and reduce swelling. Huangkui Capsules are mainly used to treat damp-heat syndrome. The above-mentioned Chinese patent medicines have obvious advantages and individualized treatment characteristics for the treatment of CGN proteinuria, but are not conducive to homogeneous treatment.

[0004] Our clinical syndrome research shows that the basic pathogenesis of CGN is spleen and kidney deficiency, the flow of essence and blood stasis throughout the course of the disease, so strengthening the spleen and kidney, consolidating essence and removing blood stasis should be the main treatment methods for CGN. The Chinese invention patent with publication number CN103251728A discloses a ginseng and di granule for treating chronic nephritis based on this method, and its effective components are in weight ratio: 2-4 parts of red ginseng, 2-4 parts of cooked rehmannia, 4-6 parts of poria, 2-4 parts of schisandra chinensis, 2-4 parts of mulberry silkworm cocoon, 2-4 parts of chicken gizzard lining, and 2-4 parts of Sichuan peony. The ginseng and di granule can effectively alleviate the clinical symptoms of patients with chronic nephritis with spleen and kidney deficiency syndrome, reduce proteinuria and erythrocytic urine formation; and by promoting renal HGF secretion and inhibiting TGF-β1 production, it plays a renal protective role and achieves the effect of curing chronic nephritis. However, the ginseng and di granule has the problem that the quality standards of some raw material components such as mulberry silkworm cocoon and chicken gizzard lining are difficult to control. Summary of the invention

[0005] In view of the above problems, the present invention provides a new Chinese medicine composition for strengthening spleen and kidney, consolidating essence and removing blood stasis, and its preparation method and application. The Chinese medicine composition is effective in treating chronic glomerulonephritis, has simple raw material composition, is easy to control quality, and is safe to use without obvious adverse reactions.

[0006] The first aspect of the present invention provides a Chinese medicine composition for strengthening the spleen and kidney, consolidating essence and removing blood stasis, which comprises the following raw materials by weight: 5-6 parts of ginseng, 8-10 parts of Rehmannia glutinosa, 8-10 parts of Poria cocos, 3-4 parts of Schisandra chinensis, and 5-6 parts of Chuanxiong. Further, it comprises the following raw materials: 5.5 parts of ginseng, 9 parts of Rehmannia glutinosa, 9 parts of Poria cocos, 3.5 parts of Schisandra chinensis, and 5.5 parts of Chuanxiong.

[0007] Traditional Chinese medicine believes that protein in the blood is a fine substance in the human body. If the spleen is weak and unhealthy, it can lead to the spleen losing control, unable to absorb essence, and the essence flowing downward; kidney deficiency causes the essence gate to be weak, the kidney cannot store essence, and the essence flows downward, which can all cause protein to be lost in the urine. The course of CGN is long, and long-term illness often causes blood stasis. Long-term illness enters the collaterals, and blood stasis is mixed in. The present invention takes "spleen and kidney deficiency, essence flowing downward, and blood stasis retention" as the key pathogenesis of CGN, and adopts the treatment method of "strengthening the spleen and kidney, consolidating essence and removing blood stasis" to optimize and develop the ginseng soup formula from "Shengji Zongluo Yao" compiled by Cheng Lin, a famous Xin'an medical doctor in the Qing Dynasty. It is mainly used to treat patients with CGN spleen and kidney deficiency, essence flowing downward, and blood stasis retention.

[0008] The whole prescription has the effects of strengthening the spleen and kidney, consolidating essence and removing blood stasis. In the prescription, ginseng and Rehmannia root are the main drugs. Ginseng strengthens the spleen and replenishes qi, while Rehmannia root nourishes the kidney and replenishes essence. The combination of the two can help each other, and the innate and acquired can be mutually supported, the positive qi can be replenished, and the deficiency can be replenished, so as to restore the function of the spleen and kidney to control the essence and store the essence. Poria cocos and Schisandra chinensis are the assistant drugs. Poria cocos strengthens the spleen and replenishes qi, while Schisandra chinensis nourishes the kidney and consolidates the essence. The combination of the two can help the main drugs to nourish the spleen and kidney at the same time and consolidate the essence. Chuanxiong is an adjuvant drug, which can promote blood circulation and remove blood stasis. CGN often has a long course of disease, and long-term illness is more blood stasis, and long-term illness enters the collaterals. Chuanxiong can remove blood stasis and regulate the kidney collaterals. The combination of various drugs can not only pay attention to the spleen and kidney, but also play the role of consolidating essence and removing blood stasis.

[0009] The raw materials of the present invention are introduced as follows:

[0010] (1) Ginseng: It is the root of Panax ginseng, a plant of the Araliaceae family. It is sweet, warm and slightly bitter in nature. It has the effects of greatly replenishing vital energy, restoring the pulse and strengthening the body, tonifying the spleen and lungs, promoting the production of body fluids and nourishing blood, and calming the mind and improving intelligence. Experimental studies have confirmed that ginsenoside Rg1 has a good protective effect on the doxorubicin nephropathy model (podocyte injury model), can reduce 24h urinary protein excretion, improve kidney pathological damage, and reduce podocyte damage. Ginsenosides Rg-1 and Rb-1 have a slow improvement effect on proteinuria in rats with adriamycin nephropathy, and have no aggravating effect on existing kidney damage.

[0011] (2) Rehmannia glutinosa: It is the rhizome of Rehmannia glutinosa or Rehmannia glutinosa of the Scrophulariaceae family, which is processed and steamed. It tastes sweet and is slightly warm in nature. It has the effects of nourishing blood and yin, replenishing essence and nourishing marrow. Clinical studies have found that Rehmannia glutinosa total glycosides capsule can significantly reduce the 24-hour urine protein quantification of patients with chronic kidney disease (CKD) stage 1 and 2, improve clinical symptoms, and has good safety. Rehmannia glutinosa total glycosides capsule combined with candesartan cilexetil is more effective in treating chronic glomerulonephritis than candesartan cilexetil alone, and has good clinical application value. Rehmannia glutinosa total glycosides combined with tripterygium wilfordii polyglycosides have better efficacy in patients with membranous nephropathy than tripterygium wilfordii polyglycosides alone, and have fewer adverse reactions.

[0012] (3) Poria cocos: It is the dried sclerotium of the fungus Poria cocos (Schw.) Wolf of the Polyporaceae family. It is mild in nature, sweet in taste, and has the effects of promoting diuresis and reducing swelling, strengthening the spleen and removing dampness. Pharmacodynamic studies have shown that the ethanol extract of Poria cocos can inhibit the excretion of urine protein, the reduction of serum total protein and globulin in the adriamycin nephrotic syndrome model, and improve the disorder of serum cholesterol metabolism and cytokine levels.

[0013] (4) Schisandra chinensis: It is the dried mature fruit of Schisandra chinensis (Turcz.) Baill., a plant of the Magnoliaceae family. It tastes sweet and sour, is slightly warm in nature, and has the effects of astringency, invigorating qi and promoting the production of body fluid, and tonifying the kidney and calming the mind. Studies have found that Schisandra chinensis compound (SM) can protect podocytes and reduce proteinuria in mice with adriamycin nephropathy (ADN) by upregulating the expression of WT1 protein, nephrin and podocin mRNA. A study using urine metabolomics technology based on gas chromatography-mass spectrometry (GC-MS) confirmed that Schisandra chinensis may play a role in treating glomerulonephritis by regulating arachidonic acid and fatty acid metabolism.

[0014] (5) Chuanxiong: It is the rhizome of the plant Chuanxiong of the Umbelliferae family. It is pungent in taste and warm in nature. It has the effects of promoting blood circulation and qi, dispelling wind and relieving pain. Clinical studies have confirmed that Chuanxiongzine injection has a significant therapeutic effect on chronic nephritis. Chuanxiongzine can significantly reduce proteinuria in patients with chronic nephritis, improve renal function, and has the effects of regulating lipids and reducing endothelin levels. Meta-analysis has confirmed that the efficacy of traditional Chinese medicine blood circulation and collateral-activating method based on Chuanxiong in the treatment of chronic nephritis is better than that of Western medicine.

[0015] The second aspect of the present invention provides a Chinese medicine preparation for strengthening the spleen and kidney, consolidating essence and removing blood stasis, comprising the aforementioned Chinese medicine composition for strengthening the spleen and kidney, consolidating essence and removing blood stasis and pharmaceutically acceptable excipients. The dosage form of the Chinese medicine preparation can be any conventional Chinese medicine oral dosage form, including but not limited to granules, tablets, capsules, pills, powders, decoctions, mixtures and oral liquids, preferably granules. The excipients include but are not limited to fillers, wetting agents, lubricants, disintegrants, flavoring agents, etc.

[0016] The third aspect of the present invention provides a method for preparing a Chinese medicine granule for strengthening the spleen and kidney, consolidating essence and removing blood stasis, comprising the following steps: taking the following raw materials according to the following weight portions: 5-6 parts of ginseng, 8-10 parts of rehmannia root, 8-10 parts of poria, 3-4 parts of schisandra chinensis, and 5-6 parts of chuanxiong; boiling and extracting with water, filtering and concentrating the decoction obtained by the extraction in turn, and then adding pharmaceutically acceptable excipients, wet granulating, and drying to obtain the granule.

[0017] Further, the method comprises the following steps: i) mixing the raw materials, adding water and boiling to extract, filtering and concentrating the decoction obtained by the extraction in sequence; or,

[0018] ii) dividing the raw materials into two or more groups, decocting them with water for extraction, combining the decoctions obtained from each group, and then filtering and concentrating them in sequence; or,

[0019] iii) dividing the raw materials into two or more groups, respectively boiling and extracting them, filtering the decoctions obtained from each group, combining the filtrates, and concentrating them; or,

[0020] iv) dividing the raw materials into two or more groups, respectively boiling and extracting them with water, filtering and concentrating the decoctions obtained from each group, and combining the concentrated solutions;

[0021] Furthermore, the weight of water extracted by decoction is 8-10 times the total weight of the raw materials, and the extraction time of decoction is 1.0-1.5h.

[0022] Furthermore, the water-adding decoction extraction is performed three times; in the first water-adding decoction extraction, the weight of water is 10 times the total weight of the raw material, and the extraction time is 1.5 hours; in the second water-adding decoction extraction, the weight of water is 8 times the total weight of the raw material, and the extraction time is 1.0 hours; in the third water-adding decoction extraction, the weight of water is 8 times the total weight of the raw material, and the extraction time is 1.0 hours.

[0023] Furthermore, the concentration is performed to a specific gravity of 1.10.

[0024] In a fourth aspect of the present invention, the use of the Chinese medicine composition or Chinese medicine preparation for strengthening the spleen and kidney, consolidating essence and removing blood stasis in the preparation of a medicine for treating chronic glomerulonephritis is provided. For example, when the Chinese medicine granules for strengthening the spleen and kidney, consolidating essence and removing blood stasis of the present invention are used to treat chronic glomerulonephritis, the method of taking is to dissolve and take warm, 3 times a day, 1 pack (10g) each time.

[0025] The beneficial effects of the present invention are:

[0026] The composition of the present invention adopts ginseng, rehmannia root, poria, schisandra chinensis and chuanxiong as raw materials and performs appropriate weight ratio, so that the raw materials complement each other, have the effects of invigorating the spleen and kidney, consolidating essence and removing blood stasis, can effectively deal with the basic pathogenesis of CGN spleen and kidney deficiency, semen and micro-bedding, and blood stasis retention, and is conducive to the homogeneous treatment of the disease.

[0027] The raw material composition of the invention is simple, the quality is easy to control, the effective rate for treating CGN spleen and kidney deficiency syndrome is high, the clinical symptoms of spleen and kidney deficiency syndrome of patients can be significantly alleviated, urine protein can be reduced, immune function can be improved, kidney inflammation response can be alleviated, and kidney protection can be exerted. The clinical efficacy combined with basic western medicine treatment is significantly better than that of simple basic western medicine treatment, and no obvious adverse reaction is observed during the medication process, and the application is safe. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1A The kidney pathological results of the normal group (HE staining ×400);

[0029] Figure 1B Renal pathological results of the model group (HE staining ×400);

[0030] Figure 1CThe kidney pathological results of the high-dose group of the Chinese medicine granules of the present invention (HE staining ×400);

[0031] Figure 1D The kidney pathological results of the medium-dose group of the Chinese medicine granules of the present invention (HE staining ×400);

[0032] Figure 1E The kidney pathological results of the low-dose group of the Chinese medicine granules of the present invention (HE staining ×400);

[0033] Figure 2A The kidney pathological results of the normal group (Masson staining ×400);

[0034] Figure 2B Renal pathological results of the model group (Masson staining ×400);

[0035] Figure 2C The kidney pathological results of the high-dose group of the Chinese medicine granules of the present invention (Masson staining × 400);

[0036] Figure 2D The kidney pathological results of the medium-dose group of the Chinese medicine granules of the present invention (Masson staining × 400);

[0037] Figure 2E The kidney pathological results of the low-dose group of the Chinese medicine granules of the present invention (Masson staining × 400);

[0038] Figure 3 It is the ultra-high performance liquid chromatography analysis spectrum of the Chinese medicine granules of the present invention;

[0039] Figure 4 This is the ultra-high performance liquid chromatography analysis spectrum of ginseng particles. DETAILED DESCRIPTION

[0040] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0041] Example 1

[0042] A Chinese medicine granule for strengthening the spleen and kidney, consolidating essence and removing blood stasis, the preparation method of which is as follows:

[0043] Take the following raw materials by weight: 5 parts of ginseng, 8 parts of Rehmannia glutinosa, 8 parts of Poria cocos, 3 parts of Schisandra chinensis, and 5 parts of Chuanxiong; add water to each raw material and boil it for three times, add 10 times the amount of water for the first time, and boil it for 1.5 hours; add 8 times the amount of water for the second and third times, and boil it for 1.0 hours. Combine the three extracts of each raw material, filter, let it stand for 48 hours, absorb the supernatant, decompress and concentrate to a specific gravity of 1.10, add dextrin as a base material, spray dry (≤80℃), granulate, sieve (upper sieve 10 mesh, lower sieve 60 mesh), package, outsource, send for inspection, and put into storage.

[0044] Example 2

[0045] A Chinese medicine granule for strengthening the spleen and kidney, consolidating essence and removing blood stasis, the preparation method of which is as follows:

[0046] Take the following raw materials by weight: 6 parts of ginseng, 10 parts of Rehmannia root, 10 parts of Poria cocos, 4 parts of Schisandra chinensis, and 6 parts of Chuanxiong; decoct and extract each raw material once with water, add 10 times the amount of water, decoct for 1.5 hours to obtain each raw material decoction, filter each raw material decoction separately, combine the filtrate, let stand and settle for 48 hours, absorb the supernatant, concentrate under reduced pressure to a specific gravity of 1.10, add dextrin as a base material, spray dry (≤80°C), granulate, sieve (upper sieve 10 mesh, lower sieve 60 mesh), package, outsource, send for inspection, and put into storage.

[0047] Example 3

[0048] A Chinese medicine granule for strengthening the spleen and kidney, consolidating essence and removing blood stasis, the preparation method of which is as follows:

[0049] Take the following raw materials by weight: 5.5 parts of ginseng, 9 parts of Rehmannia glutinosa, 9 parts of Poria cocos, 3.5 parts of Schisandra chinensis, and 5.5 parts of Chuanxiong; add water and boil for extraction three times, add 10 times the amount of water for the first time, boil for 1.5 hours; add 8 times the amount of water for the second and third times, boil for 1.0 hours. Combine the extracts, filter, let stand for 48 hours, absorb the supernatant, decompress and concentrate to a specific gravity of 1.10, add dextrin as a base material, spray dry (≤80℃), granulate, sieve (upper sieve 10 mesh, lower sieve 60 mesh), package, outsource, send for inspection, and put into storage.

[0050] Comparative Example

[0051] The ginseng particles were prepared according to the method of Example 1 described in Chinese invention patent publication number CN103251728A.

[0052] Test example

[0053] 1. Clinical trial research:

[0054] All the subjects were from the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, and the study period was from December 2018 to December 2021. According to the inclusion criteria, 300 patients with CGN were selected and randomly divided into an experimental group of 150 cases and a control group of 150 cases. Inclusion criteria: ① Age 18 to 65 years old, ② Meet the diagnostic criteria of CKD stage 1-2 (GFR>60mL / min·1.73m 2 ); ③ Urine protein <2g in 24 hours before enrollment; ④ No use of ACEI / ARB drugs or Chinese patent medicines within 2 weeks before enrollment, or use but after a 2-week washout period; ⑤ Approved by the hospital ethics committee.

[0055] The control group was given basic western medicine treatment (including diet control, blood pressure adjustment, etc.). The experimental group was given basic western medicine treatment + oral administration of the Chinese medicine granules of the present invention (Example 3). The method of administration was to dissolve and take warm, 3 times a day, 1 pack (10g) each time. The course of treatment for both groups was 12 weeks.

[0056] A total of 277 subjects actually completed the 12-week treatment course, including 141 in the experimental group and 136 in the control group, with a dropout rate of 7.67%. There was no statistical difference in gender, age, disease course, and CKD stage between the two groups, and they were comparable. See Table 1.

[0057] Table 1 Comparison of general information of patients

[0058]

[0059] Research findings:

[0060] (1) Comparison of TCM syndrome efficacy evaluation

[0061] TCM syndrome efficacy evaluation criteria: revised with reference to the "Chronic nephritis syndrome efficacy evaluation criteria" in the 2002 "Guidelines for Clinical Research of New Chinese Medicines (Trial)". The efficacy is mainly evaluated by the symptom score of spleen and kidney deficiency syndromes such as back pain, fatigue, facial swelling, limb swelling, poor appetite or abdominal distension.

[0062] ①Clinical cure: the symptom score is reduced by ≥95%. ②Markedly effective: the symptom score is reduced by ≥70%. ③Effective: the symptom score is reduced by ≥30%. ④Ineffective: There is no significant improvement in TCM clinical symptoms and signs, or even aggravation, and the symptom score is reduced by <30%.

[0063] Calculation formula: [(score before treatment - score after treatment) ÷ score before treatment] × 100%.

[0064] Effective rate of TCM syndrome improvement = number of effective cases / total number of cases × 100%

[0065] Results: The total effective rate of TCM syndrome in the experimental group was 86.52%, which was significantly higher than that in the control group (46.32%). 2 =35.158, P=0.000), see Table 2.

[0066] Table 2 Comparison of TCM syndrome efficacy evaluation

[0067]

[0068] (2) Disease efficacy evaluation

[0069] Disease efficacy evaluation criteria: Revised with reference to the "Disease efficacy evaluation criteria for chronic nephritis" in the 2002 "Guidelines for Clinical Research of New Chinese Medicines (Trial)".

[0070] ① Complete remission: 24-hour urine protein quantitative <0.2g / 24h. ② Basic remission: 24-hour urine protein quantitative decreases by >50% compared with the initial value. ③ Effective: 24-hour urine protein quantitative decreases between 25%-50%. ④ Ineffective: 24-hour urine protein quantitative is still higher than the above standard.

[0071] Effectiveness of 24-hour urine protein quantitative test = (number of effective cases + number of stable cases) / total number of cases × 100%

[0072] Results: The total effective rate of the experimental group was 80.14%, significantly higher than that of the control group (65.44%). 2 =6.071, P=0.016), see Table 3.

[0073] Table 3 Comparison of disease efficacy evaluation

[0074]

[0075] (3) Comparison of 24-hour urine protein and urine red blood cell count among the patients in each group

[0076] After 12 weeks of treatment, the 24h urine protein quantity (24h Upro) and urine red blood cell count levels of the control group were lower than those before treatment (P < 0.05), and the 24h urine protein quantity (24h Upro) and urine red blood cell count of the experimental group were significantly lower than those before treatment, and the experimental group was significantly better than the control group (P < 0.05). See Table 4.

[0077] Table 4 Comparison of 24-hour urine protein and urine red blood cell count in each group

[0078]

[0079] Note: Compared with the same group before treatment, #P<0.05; compared with the control group during the same period, *P<0.05.

[0080] (4) Comparison of renal function (serum creatinine, urea nitrogen, estimated glomerular filtration rate) among the groups

[0081] After 12 weeks of treatment, the levels of urea nitrogen, serum creatinine, and estimated glomerular filtration rate (eGFR) in the control group and the experimental group did not change significantly compared with those before treatment (P>0.05). See Table 5.

[0082] Table 5 Comparison of renal function among groups

[0083]

[0084] Note: Compared with the same group before treatment, # P<0.05; compared with the control group during the same period, *P<0.05. eGFR: estimated glomerular filtration rate.

[0085] (5) Immune function of patients in each group (CD4 + T, CD8 + T) Comparison

[0086] Before treatment, the whole blood CD4 + T, CD8 + There was no statistical difference in T level (P>0.05), CD4 + The T level was lower than that in the normal group (P<0.05), and CD8 + After treatment, the CD4 + T levels and CD4 + T / CD8 + T ratios were higher than those before treatment (P<0.05), CD8 + The T levels were lower than those before treatment (P<0.05), and the experimental group was better than the control group (P<0.05). See Table 6.

[0087] Table 6 Whole blood CD4 of three groups + T, CD8 + T level comparison

[0088]

[0089] Note: Compared with the normal group, * P<0.05; compared with the group before treatment, # P<0.05; compared with the control group, ▲ P<0.05.

[0090] (6) Safety indicators and adverse event observation

[0091] Among all the patients, 2 cases experienced nausea, which was judged by the researchers to be unrelated to the trial medication. After symptomatic treatment, both cases were relieved and cured, and continued to enter clinical observation research. After treatment, the safety indicators of the trial group, such as liver transaminases, electrolytes, routine stool + occult blood, and electrocardiogram, showed no significant changes compared with those before treatment. No serious adverse events occurred during the observation period.

[0092] 2. Animal Experimental Research

[0093] 50 SPF male SD rats were selected and randomly divided into 5 groups, including sham operation group, model group, high dose group of Chinese medicine granules of the present invention, medium dose group of Chinese medicine granules of the present invention, and low dose group of Chinese medicine granules of the present invention, 10 rats each. Mesangial proliferative glomerulonephritis (MsPGN) model was established in all rats except the sham operation group. All rats in each group were fed with fixed animal feed; the low, medium and high dose groups of Chinese medicine were given the aqueous solution of Chinese medicine granules of Example 3 of the present invention by gavage at 4.0g / kg·d, 8.0g / kg·d and 16.0g / kg·d respectively; the sham operation group and the model group were gavaged with an equal amount of distilled water (3mL); the administration was continued for 8 weeks. Enzyme-linked immunosorbent assay (ELISA) was used to detect 24-hour urine protein (24h Upro) and the contents of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), fibronectin (FN), type IV collagen (Col-IV) in serum, as well as reactive oxygen species (ROS), superoxide dismutase (SOD) activity, and malondialdehyde (MDA) content in renal tissue; HE and Masson staining were used to observe renal pathological changes. During the experiment, one animal died in each of the normal group and the medium-dose group of the Chinese medicine granules of the present invention, and one animal died in each of the model group and the high-dose and low-dose groups of the Chinese medicine granules of the present invention.

[0094] Study Results

[0095] (1) Comparison of 24-hour urine protein in each group of rats (ELISA method)

[0096] Compared with the normal group, the 24h urine protein content of the model group rats was significantly increased, and the difference was statistically significant (P < 0.01). Compared with the model group, the 24h urine protein content of the rats in the high, medium and low dose groups of the Chinese medicine granules of the present invention was significantly lower than that in the model group (P < 0.01); the medium dose group of the Chinese medicine granules of the present invention performed best. See Table 7.

[0097] Table 7 Comparison of 24-hour urine protein in each group of rats

[0098]

[0099]

[0100] Note: Compared with the normal group: ▲ P<0.01; compared with the model group: ■ P<0.01, ★ P<0.05.

[0101] (2) Renal pathological manifestations of rats in each group (HE, Masson staining)

[0102] HE and Masson staining of the kidneys of rats in each group: The kidneys of rats in the model group showed diffuse mesangial cell proliferation with increased matrix, enlarged glomerular volume, increased number of cells in the glomerulus, infiltration of a large number of neutrophils, narrowed capillary lumen, infiltration of inflammatory cells in the tubular interstitium, and mild fibrosis. The kidneys of rats in each dose group of the Chinese herbal granules of the present invention showed enlarged glomerular volume, moderate to severe hyperplasia of glomerular mesangial cells and endothelial cells, and infiltration of mononuclear cells; the mesangial area became wider, the mesangial matrix increased, the Bowman's bursa expanded, the extracellular matrix increased significantly, and diffuse mesangial cell proliferation accompanied by increased matrix. Among them, the medium dose group of the Chinese herbal granules of the present invention had the mildest degree of damage. Figures 1A to 1E and Figures 2A to 2E .

[0103] (3) Comparison of the levels of MMP-9, TIMP-1, FN, and Col-Ⅳ in the serum of rats in each group (ELISA method)

[0104] Compared with the normal group, the levels of MMP-9, TIMP-1, FN, and Col-Ⅳ in the model group were significantly increased, and the difference was statistically significant (P < 0.01). Compared with the model group, the levels of MMP-9, TIMP-1, FN, and Col-Ⅳ in the high, medium, and low dose groups of the Chinese medicine granules of the present invention were all reduced, and the difference was statistically significant (P < 0.05). See Table 8.

[0105] Table 8 Comparison of serum MMP-9, TIMP-1, FN and Col-Ⅳ levels in rats of each group

[0106]

[0107]

[0108] Note: Compared with the normal group, # P<0.05; compared with the model group, * P<0.05.

[0109] (4) Quantitative comparison of ROS, SOD and MDA in the kidneys of rats in each group (ELISA method)

[0110] Compared with the normal group, the ROS and MDA levels of the model group rats were significantly increased, and the SOD level was significantly decreased, and the difference was statistically significant (P < 0.01). Compared with the model group, the ROS and MDA levels of the high, medium and low dose groups of the Chinese medicine granules of the present invention were all reduced, and the SOD level was all increased, and the difference was statistically significant (P < 0.05). See Table 9.

[0111] Table 9 Comparison of ROS, SOD and MDA contents in kidney of rats in each group

[0112]

[0113] Note: Compared with the normal group: ▲ P<0.01; compared with the model group: ■ P<0.01, ★ P<0.05.

[0114] 3. Comparative study of the Chinese medicine granules of the present invention and Shendi granules (comparative sample)

[0115] (1) Ultra-high performance liquid chromatography analysis of the Chinese medicine granules of the present invention and Shendi granules

[0116] The single active ingredients in the composition of Shendi Granules are mainly found in five medicines: ginseng, cooked rehmannia, poria, schisandra chinensis, and chuanxiong; while the active ingredients of two insect medicines, mulberry silkworm cocoon and chicken gizzard lining, cannot be detected, resulting in poor control of the quality standard of Shendi Granules. The results of chromatographic analysis indicate that the content of active ingredients in the Chinese medicine granules of the present invention is roughly equivalent to that in Shendi Granules. Figure 3 and Figure 4 , Table 10. Among them, the chromatographic sample information of the Chinese medicine granules of the present invention is as follows: injection number 1, injection volume 3.00 μL, running time 25.0 min, channel name: PDA Ch2 320nm@4.8nm. Peak result: retention time 5.417 minutes, area 78134 microvolts·seconds, height 10965 microvolts; the chromatographic sample information of the Shendi granules is as follows: injection number 1, injection volume 2.00 μL, running time 25.0 min, channel name: PDA Ch2 320nm@4.8nm. Peak result: retention time 15.361 minutes, area 309187 microvolts·seconds, height 43820 microvolts.

[0117] Table 10 Drug composition and single active ingredients of Shendi Granules

[0118]

[0119] (2) Comparative study on the clinical pharmacodynamics of the Chinese medicine granules of the present invention and Shendi granules

[0120] ① Comparison of 24-hour urine protein and urine red blood cell count between the two groups

[0121] After 12 weeks of treatment with the Chinese medicine granules of the present invention, the 24h urine protein quantity (24h Upro) and urine red blood cell count levels were significantly reduced compared with those before treatment (P < 0.05); and there was no significant difference compared with the Shendi granules group after 12 weeks of treatment (P > 0.05). See Table 11.

[0122] Table 11 Comparison of 24-hour urine protein and urine red blood cell count of the Chinese medicine granules of the present invention and Shendi granules

[0123]

[0124]

[0125] Note: Compared with the same group before treatment, # P<0.05; compared with the control group during the same period, *P<0.05.

[0126] ②Comparison of renal function (serum creatinine, urea nitrogen, estimated glomerular filtration rate) between the two groups

[0127] After 12 weeks of treatment, the levels of urea nitrogen, blood creatinine, and estimated glomerular filtration rate (eGFR) in the Chinese medicine granule group and the Shendi granule group showed no significant changes compared with those before treatment (P>0.05), and there was no significant change in urea nitrogen, blood creatinine, and eGFR between the two groups after treatment (P>0.05). See Table 12.

[0128] Table 12 Comparison of renal function in each group

[0129]

[0130] Note: Compared with the same group before treatment, #P<0.05; compared with the control group during the same period, *P<0.05. eGFR: estimated glomerular filtration rate.

[0131] ③Evaluation of disease efficacy in the two groups of patients

[0132] Results: The total effective rate of the disease treatment in the Chinese medicine granule group was 80.00%, and the total effective rate of the disease treatment in the Shendi granule group was 82.25%, and there was no significant difference between the two groups (χ 2 =0.003, P=0.953), see Table 13.

[0133] Table 13 Comparison of disease efficacy evaluation

[0134]

[0135] IV. Research Conclusion

[0136] (1) Clinical trial research

[0137] ① The clinical symptoms of the patients in the test group can be significantly improved by taking the Chinese medicine granules of the present invention, and the total effective rate of Chinese medicine syndrome efficacy and the total effective rate of disease efficacy are significantly better than those in the control group.

[0138] ② The Chinese medicine granules of the present invention can significantly reduce urine protein, reduce the number of red blood cells in urine, and improve immune function.

[0139] ③ The Chinese medicine granules of the present invention have good safety.

[0140] (2) Animal Experimental Research

[0141] The Chinese medicinal granules of the present invention can significantly reduce the renal pathological damage of rats with mesangial proliferative glomerulonephritis (MsPGN), and the mechanism thereof is related to resisting oxidative stress, inhibiting the inflammatory response of the renal tissue of MsPGN rats, and thus exerting a renal protective effect.

[0142] (3) Comparative study with ginseng granules

[0143] The clinical efficacy of the Chinese medicine granules of the present invention and the Shendi granules in treating chronic nephritis is not significantly different, but the prescription is simplified and the quality control is easy.

[0144] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

Claims

1. A Chinese medicine composition for strengthening the spleen and kidney, consolidating essence and removing blood stasis, It is characterized in that By weight, it includes the following raw material components: 5-6 parts of ginseng, 8-10 parts of rehmannia root, 8-10 parts of tuckahoe, 3-4 parts of schisandra chinensis, and 5-6 parts of chuanxiong.

2. The Chinese medicine composition for strengthening the spleen and kidney, consolidating essence and removing blood stasis according to claim 1, It is characterized in that By weight, it includes the following raw material components: 5.5 parts of ginseng, 9 parts of rehmannia root, 9 parts of tuckahoe, 3.5 parts of schisandra chinensis, and 5.5 parts of chuanxiong.

3. A Chinese medicine preparation for strengthening the spleen and kidney, consolidating essence and removing blood stasis, It is characterized in that The invention comprises the Chinese medicine composition for strengthening the spleen and kidney, consolidating essence and removing blood stasis as claimed in claim 1 or 2 and pharmaceutically acceptable excipients.

4. The Chinese medicine preparation for strengthening the spleen and kidney, consolidating essence and removing blood stasis according to claim 3, It is characterized in that The dosage form of the traditional Chinese medicine preparation is selected from any one of granules, tablets, capsules, pills, powders, decoctions, mixtures and oral liquids.

5. A method for preparing a Chinese medicine granule for strengthening the spleen and kidney, consolidating essence and removing blood stasis, It is characterized in that The steps include: Take the following raw materials by weight: 5-6 parts of ginseng, 8-10 parts of rehmannia root, 8-10 parts of poria, 3-4 parts of schisandra chinensis, and 5-6 parts of chuanxiong; add water for decoction and extraction, filter and concentrate the extracted decoction in turn, then add pharmaceutically acceptable excipients, wet granulate and dry to obtain the product.

6. A method for preparing the Chinese medicine granules for strengthening the spleen and kidney, consolidating essence and removing blood stasis according to claim 5, It is characterized in that The steps include: i) mixing the raw materials, adding water and boiling to extract, filtering and concentrating the decoction obtained by extraction; or, ii) dividing the raw materials into two or more groups, decocting them with water for extraction, combining the decoctions obtained from each group, and then filtering and concentrating them in sequence; or, iii) dividing the raw materials into two or more groups, respectively boiling and extracting them, filtering the decoctions obtained from each group, combining the filtrates, and concentrating them; or, iv) Dividing the raw materials into two or more groups, respectively boiling and extracting them with water, filtering and concentrating the decoctions obtained from each group, and combining the concentrated solutions.

7. A method for preparing the Chinese medicine granules for strengthening the spleen and kidney, consolidating essence and removing blood stasis according to claim 5 or 6, It is characterized in that The weight of the water extracted by decoction is 8-10 times the total weight of the raw materials, and the extraction time of the decoction is 1.0-1.5h.

8. A method for preparing the Chinese medicine granules for strengthening the spleen and kidney, consolidating essence and removing blood stasis according to claim 7, It is characterized in that The water-adding decoction extraction is performed three times; in the first water-adding decoction extraction, the weight of water is 10 times the total weight of the raw material, and the extraction time is 1.5 hours; in the second water-adding decoction extraction, the weight of water is 8 times the total weight of the raw material, and the extraction time is 1.0 hours; in the third water-adding decoction extraction, the weight of water is 8 times the total weight of the raw material, and the extraction time is 1.0 hours.

9. A method for preparing the Chinese medicine granules for strengthening the spleen and kidney, consolidating essence and removing blood stasis according to claim 5 or 6, It is characterized in that The concentration is to a specific gravity of 1.

10.

10. Use of the Chinese medicinal composition for strengthening the spleen and kidney, consolidating essence and removing blood stasis as claimed in any one of claims 1-2 or the Chinese medicinal preparation for strengthening the spleen and kidney, consolidating essence and removing blood stasis as claimed in any one of claims 3-4 in the preparation of a medicine for treating chronic glomerulonephritis.

Citation Information

Patent Citations

  • Red ginseng-prepared rehmannia root particles for treating chronic nephritis and preparation method thereof

    CN103251728A